Tagged as: Biosimilars News

Association of Accessible Medicines: Ensuring the Future of Accessible Medicines in the U.S.

The Association of Accessible Medicines (“AAM”) released a white paper on avoiding shortages and ensuring drug competition for patients in America.  AAM is advocating for the uninterrupted availability of lower-cost generic and biosimilar medicines.  In the paper, AAM asserts that by placing biosimilar medicines on a level competitive playing field with…

Read More

Study Shows that Celltrion’s Infliximab Biosimilar is Comparable to Reference Infliximab and Adalimumab

According to a Celltrion press release, this week investigators presented twelve-month data from a UK-wide, three-year prospective observational study showing comparable efficacy between CT-P13 (Celltrion’s biosimilar infliximab), reference infliximab (Johnson and Johnson’s Remicade), and adalimumab (AbbVie’s Humira). The press release reports that the Personalised Anti-TNF therapy in Crohn’s disease Study…

Read More

Express Scripts and Walgreens Expand Their Group Purchasing to Include Biosimilars

Express Scripts and Walgreens Boots Alliance announced this week that “they are expanding their group purchasing efforts to include the procurement of specialty brand drugs,” including biosimilars.  According to Tim Wentworth, Express Scripts President and CEO, “[s]pecialty medications represent the most costly and complex drugs.  By expanding our efforts with Walgreens Boots Alliance, we…

Read More

American College of Rheumatology White Paper Encourages Use of Biosimilars

Last week, the American College of Rheumatology (ACR) published a new white paper “encourag[ing] providers to incorporate [biosimilars] into the treatment plans of patients with rheumatic diseases where appropriate.” The paper, titled “The Science Behind Biosimilars — Entering a New Era of Biologic Therapy,” discusses the regulatory regime for biosimilars,…

Read More